Obesity, Type 2 Diabetes
Conditions
Keywords
Obesity, Diabetes
Brief summary
Weight loss is effective in reducing many complications of obesity, with the majority of patients who undergo bariatric surgery having substantial improvements in their weight-related illnesses. The investigators propose a pilot study in 45 subjects with mild to moderate obesity to compare how losing 10% of initial body weight via one of three common weight loss strategies (medical weight loss with a low calorie diet, Roux-en-Y gastric bypass surgery, and adjustable gastric banding) affects diabetes. While the investigators do not expect this pilot study to provide definitive answers, it will provide valuable information to design a larger trial which will help guide therapy for people with mild-moderate obesity and substantial comorbidities.
Interventions
PROCEDUREGastric Banding
Laparoscopic Adjustable Gastric Banding using the LapBand
BEHAVIORALMedical Weight Loss
Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
PROCEDUREGastric Bypass
Laparoscopic Roux-en-Y Gastric Bypass
Sponsors
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Johns Hopkins University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
21 Years to 64 Years
Healthy volunteers
No
Inclusion criteria
* BMI 30-40 kg/m2 at screening visit 1 * Age 21-64 years * Insured by collaborating insurance plan (Employee Health Plan) * Type 2 Diabetes * Medically safe to undergo surgery and approved by a psychologist * Able to exercise at a moderate level * Able to give informed consent * Willing to accept randomization to each group * Able to communicate (both written and oral) in English * Willing to use reliable method of birth control during study and ≥18 months postop (if applicable)
Exclusion criteria
* Prior bariatric surgery * Prior gastric, small or large bowel, spleen, pancreas, kidney, or liver surgery, including large ventral hernia or previous large ventral hernia repair. * Weight loss of ≥ 5% of body weight in the past 6 months * Uncontrolled diabetes (HbA1c\>8.5%) * Untreated severe diabetic retinopathy * Use of thiazolidinediones or insulin currently or within the past 3 months * Uncontrolled blood pressure (\>160/100 -may be rescreened) * Estimated glomerular filtration rate (GFR)\<30 * Malignancy (except squamous or basal cell of the skin) in the past 5 years * MI, stroke or cardiovascular procedure within 12 months * Known HIV positive or use of anti-HIV therapy (HAART) * Unstable angina * Significant pulmonary disease with oxygen dependency * Chronic use (including in the past 6 months) of medications likely to cause weight gain or prevent weight loss (e.g. corticosteroids, lithium) * Use of prescription weight loss medication or over-the-counter orlistat in the past 6 months * Other serious medical condition likely to hinder accurate measurement of weight, or for which weight loss is contraindicated, or which would cause weight loss * History of severe depression requiring hospitalization in the past 12 months * Severe mental illness including bipolar disorder, schizophrenia or other psychotic disorders * Current bulimia nervosa * Unable or unwilling to use meal replacement products * Consumption of \>14 alcoholic drinks/week or \> 5 drinks on more than 2 occasions in the past 12 months * Use of illicit substances in the past 12 months * Cigarette or cigar smoking in the past 2 months * Pregnant or nursing within past 6 months * Plans to become pregnant within 2 years * Plans to relocate from the area within 1 year * Another member of household is a study participant or staff in the trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in HbA1c from baseline to final data collection | Average time 6 months | Participants will be followed until they reach 10% weight loss, anticipated average time 6 months, or up to 9 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in insulin secretion | Average time 6 months | Participants will be followed until they reach 10% weight loss, and anticipated average of 6 months, or up to 9 months. |
Countries
United States
Outcome results
None listed